Hydrophobically modified chitosan compositions
Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).
1. A polymer composition comprising an effective amount of a hydrophobically-modified chitosan, the hydrophobically-modified chitosan having saturated hydrocarbon groups attached to the chitosan backbone through amide linkages, wherein the composition is formulated as a liquid, gel, or foam with a pH of about 5 or less.
2. The polymer composition of claim 1 , wherein the hydrophobically-modified chitosan has about 1% to about 10% of available amines substituted with a saturated hydrocarbon group.
3. The polymer composition of claim 2 , wherein the hydrophobically-modified chitosan has less than about 3% of available amines substituted with a saturated hydrocarbon group.
4. The polymer composition of claim 3 , wherein the saturated hydrocarbon group is a linear C14, C16, or C18 hydrocarbon moiety.
5. The polymer composition of claim 4 , wherein the chitosan is a medium molecular weight chitosan.
6. The polymer composition of claim 2 , wherein the hydrophobically-modified chitosan has 2 or 3 different saturated hydrocarbon groups conjugated along the chitosan backbone.
7. The polymer composition of claim 6 , having a population of C6 to C12 hydrocarbon groups, and a population of C14 to C18 hydrocarbon group.
8. The polymer composition of claim 7 , wherein the hydrophobic groups further comprise C1 to C4 hydrocarbon groups.
9. The polymer composition of claim 1 , wherein the composition is formulated in a dilute organic acid, the organic acid having a pKa of from about 2 to about 5.
10. The polymer composition of claim 9 , wherein the organic acid is lactic acid, acetic acid, formic acid, or malic acid.
11. The polymer composition of claim 9 , wherein the hydrophobically-modified chitosan is present at 0.1 to about 5% by weight.
12. The polymer composition of claim 9 , wherein the organic acid is present in the composition from about 0.05M to 0.4M.
13. The polymer composition of claim 1 , wherein the composition further comprises at least one synthetic polymer.
14. The polymer composition of claim 13 , wherein the synthetic polymer is a polythene, polystyrene, polyacrylate, polyamide, polyester, polyurethane, polysulfide, or polycarbonate.
15. The polymer of composition of claim 14 , wherein the synthetic polymer is polyethylene glycol.
16. A polymer composition comprising from about 0.1 wt % to about 5 wt % of a hydrophobically-modified chitosan in dilute organic acid, the hydrophobically-modified chitosan comprising from about 0.1% to about 5% of available amines substituted with a linear C14 to C18 saturated hydrocarbon group through amide linkages.
17. The polymer composition of claim 16 , wherein the chitosan is a medium molecular weight chitosan.
18. The polymer composition of claim 16 , wherein the hydrophobically-modified chitosan is present at from about 1 wt % to about 3 wt %.
19. The polymer composition of claim 16 , wherein the dilute organic acid is present in the composition from about 0.05M to about 0.4M.
20. The polymer composition of claim 16 , wherein the dilute organic acid is present in the composition from about 0.1M to about 0.2M.
21. A method for treating a wound in a patient, comprising, applying the polymer composition of claim 1 to a wound.
22. A method for treating a wound in a patient, comprising, applying the polymer composition of claim 16 to a wound.
23. The method of claim 21 , wherein the wound has high exudate or blood flow.
24. The method of claim 21 , wherein the wound is selected from a pressure sore, diabetic ulcer, leg ulcer, donor site, graft site, surgical wound, skin abrasion or laceration, 1st or 2nd degree burn, and trauma wound.